More Articles Back to Article
Chinese regulators approve marketing authorization for Tagrisso
AstraZeneca's Tagrisso received a marketing authorization from the National Medical Products Administration in China. The drug was approved by Chinese regulators in 2017 to treat small-cell lung cancer. European Pharmaceutical Review (UK) (9/5)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!